Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Katherine Bock - VP, IR & Corporate Strategy Terry Rosen - Co-Founder, Chairman & CEO Robert Goeltz - Principal Financial & Accounting Officer & CFO Jennifer Jarrett - COO & Director Juan Jaen - Co-Founder, President & Director Kartik Krishnan - SVP, Clinical Development Conference Call Participants Alethia Young - Cantor Fitzgerald & Co. Peter Lawson - Barclays Bank Geoffrey Porges - SVB Leer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-389 ...

Pipeline and Clinical Trials - Arcus Biosciences is rapidly advancing five clinical-stage product candidates, including AB154 (Domvanalimab), AB308, AB122 (Zimberelimab), AB928 (Etrumadenant), and AB680 [7] - Six Arcus-sponsored randomized trials are expected to yield preliminary data in 2021 [7] - A Phase 3 trial, PACIFIC-8, in Stage III NSCLC, is being conducted in clinical collaboration with AstraZeneca, with registrational trial initiation expected in 2H21 [7] - Interim analysis for the ARC-7 trial (Dom + Zim in 1L NSCLC, PD-L1 ≥ 50%) is planned for 2Q21 [7] Financial Position and Partnerships - As of December 31, 2020, Arcus Biosciences had approximately $735 million in cash, with an additional $220 million from Gilead's equity investment in February 2021, providing funding through at least 2023 [7] - Gilead partnership provides significant financial and other resources to exploit the portfolio fully [7] - Gilead increased their equity stake to 195% in 1Q21, with a $220 million investment in Arcus [18] Key Programs and Molecules - Domvanalimab (anti-TIGIT mAb) is advancing into a registrational study, and AB308 (anti-TIGIT mAb) has received IND clearance, reinforcing Arcus as a leader in anti-TIGIT therapies [23] - AB680, a first-in-class small-molecule CD73 inhibitor, has shown a manageable safety profile and early clinical activity signs in combination with NP/Gem and zimberelimab in 1L metastatic pancreatic cancer, with a 41% objective response rate (7/17 patients) [96] - Zimberelimab (anti-PD-1) is being advanced into the ARC-10 registrational study in 1Q21, supporting potential approvals of both zim monotherapy and in combination with domvanalimab [110] Etrumadenant (A2aR / A2b R antagonist) - Initial randomized data from the Etruma + Zim + Carbo/Pem vs Zim + Carbo/Pem trial in TKI R/R EGFR+ NSCLC is expected in 2H21 [16] - Preliminary data from an initial cohort of the Etruma + Zim + SOC vs SOC trial in 2L/3L metastatic castrate-resistant prostate cancer (mCRPC) is expected in 2Q21, with initial randomized data in 2H21 [16] - Initial randomized data for 2L/3L cohorts and single-arm data for 3L+ of the Etruma + Zim + FOLFOX vs SOC trial in colorectal cancer is expected in 1H22 [16]

OUR VISION: COMBINING TO CURE WITH BEST-IN-CLASS CANCER THERAPIES COWEN HEALTHCARE CONFERENCE MARCH 2, 2021 NYSE: RCUS Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding future events or results contained in this presentation are forward-looking statements, including statements ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38419 Arcus Biosciences, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47 ...

Pipeline and Strategy - Arcus Biosciences has an advanced pipeline targeting TIGIT, Adenosine, and PD-1 pathways[7] - Domvanalimab (anti-TIGIT mAb) is rapidly advancing in randomized combinations[7] - Zimberelimab (anti-PD-1 mAb) enables portfolio combination strategies with a clear path to commercialization[7] - Arcus is uniquely positioned with intra-portfolio combinations not available to other companies[7] Financial Position and Collaboration - Arcus Biosciences has over $825 million in cash[7] - The Gilead collaboration provides resources and expertise to exploit multiple intraportfolio opportunities[7] Clinical Development and Milestones - Preliminary randomized data from ongoing trials are expected in multiple settings and combinations[7] - Interim analysis of Domvanalimab and Zimberelimab in 1L NSCLC (ARC-7) is expected in the first half of 2021[24] - Preliminary Phase 1/1b data for AB680 in 1L PDAC (ARC-8) is expected in Q1 2021[24] Clinical Activity - In late-line mCRC, Etruma + mFOLFOX-6 showed a disease control rate (DCR) of 76%[57] - In patients with 3L+ mCRC, Etruma + mFOLFOX-6 showed a DCR of 64%[57]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 Arcus Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3898 ...

OUR VISION: COMBINING TO CURE WITH BEST-IN-CLASS CANCER THERAPIES NYSE: RCUS JUNE 2020 Forward-looking Statements/Safe Harbor This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements, including statements about our vision, strategy, ...